



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
HOSMANE et al.

Serial No. 10/679,429

Filed: October 7, 2003

For: RING EXPANDED NUCLEOSIDES AND NUCLEOTIDES

Confirmation No. 3460  
Attny. Docket No. 46481  
Group Art Unit: 1623  
Examiner: Khare, D.

**FILED UNDER RULE 1.116  
EXPEDITED PROCEDURE**

**TRANSMITTAL OF RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. *(Small entity fees indicated in parentheses.)*

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
<b>Total Claims</b>	46	-	46	0	50.00	\$0
<i>(Small Entity)</i>					<i>(25.00)</i>	
<b>Independent claims</b>	8	-	8	0	200.00	\$0
<i>(Small Entity)</i>					<i>(100.00)</i>	
<b>Multiple Dependent</b>	0	-	0	0	360.00	0
<i>(Small Entity)</i>					<i>(180.00)</i>	
<b>Extension of Time</b>	<b>One Month</b>		<b>Two Months</b>	<b>Three Months</b>	<b>Four Months</b>	
<b>Fee</b>	\$120		\$450	\$1,020	\$1,590	\$1,020.00
<i>(Small Entity)</i>	<i>(\$60)</i>		<i>(\$225)</i>	<i>(\$510)</i>	\$795	
<b>IDS</b>						\$0
<b>Total</b>						\$1,020.00

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate. **CUSTOMER NO. 20736**

Respectfully submitted,

Paul E. White, Jr.  
Reg. No. 32,011  
Tel. No. 202-261-1050  
Fax No. 202-887-0336

Date: **January 23, 2006**  
January 22, 2006=Sunday

Manelli Denison & Selter, PLLC  
2000 M Street, N.W.  
Suite 700  
Washington, D.C. 20036-3307  
202.261.1000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
HOSMANE, et al.

Confirmation No: 3460  
Atty. Docket No. 46481

Appln. No.: 10/679,429

Group Art Unit: 1623  
Examiner: Khare, D.

Filed: October 7, 2003

Title: RING EXPANDED NUCLEOSIDES AND NUCLEOTIDES

\* \* \* \* \*

January 23, 2006  
(January 22, 2006=Sunday)

**RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Reconsideration and allowance of this application is respectfully requested in view of the following new observations, referencing new technical journal articles.

The applicants note with appreciation in the Office Action dated July 22, 2005, the withdrawal of the rejection of claims 24-69 under the judicially created doctrine of obviousness-type double patenting over claims in U.S. Patent No. 6,677,310.

In response to the Office Action, the applicants respectfully traverse the rejection of claims 24-69 under 35 USC 102(e) in view of Hosmane et al. ,USP 5,843,912. This reference does not anticipate the presently claimed invention or make it obvious.

The applicants assert that the Office Action refers to non-existing passages in the cited reference of Hosmane et al. The Office Action states that the formulas II, III and IV compounds of Hosmane et al. are disclosed at column 15, lines 25-65 and column 16,